kabutan

BrightPath Biotherapeutics Co., Ltd.(4594) Summary

4594
TSE Growth
BrightPath Biotherapeutics Co., Ltd.
55
JPY
-1
(-1.79%)
Apr 30, 10:22 am JST
0.34
USD
Apr 29, 9:22 pm EDT
Result
PTS
outside of trading hours
55.9
Apr 30, 10:21 am JST
Summary Chart Historical News Financial Result
PER
PBR
7.02
Yield
ー%
Margin Trading Ratio
6.24
Stock Price
Apr 30, 2026
Opening Apr 30, 9:00 am
55 JPY 0.34 USD
Previous Close Apr 28
56 JPY 0.35 USD
High Apr 30, 9:56 am
56 JPY 0.34 USD
Low Apr 30, 9:03 am
54 JPY 0.33 USD
Volume
973,800
Trading Value
0.05B JPY 0.33M USD
VWAP
54.71 JPY 0.34 USD
Minimum Trading Value
5,500 JPY 34 USD
Market Cap
7.64B JPY 0.05B USD
Number of Trades
75
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
Slightly High
1-Year Average
795
1-Year High Aug 15, 2025
10,957
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 1,455,600 20,760,300 14.26
Apr 17, 2026 1,455,600 19,345,400 13.29
Apr 10, 2026 1,480,200 19,796,200 13.37
Apr 3, 2026 1,464,600 19,434,900 13.27
Mar 27, 2026 1,474,700 19,430,000 13.18
Company Profile
BrightPath Biotherapeutics Co., Ltd. is a biotech venture originating from Kurume University, focusing on cancer immunotherapy using NKT cells and antibody drugs.
Sector
Pharmaceuticals
BrightPath Biotherapeutics Co., Ltd. is a drug discovery venture specializing in the development of cancer immunotherapy drugs, originating from Kurume University. The company has multiple pipelines ranging from exploratory research to early clinical trial stages, with a business model that generates revenue by licensing out to domestic and international pharmaceutical companies for late-stage clinical trials and beyond. Major development pipelines include iPS cell-derived NKT cell therapy, CAR-T cell therapy, antibody drugs, and personalized neoantigen vaccines. Notably, in the field of iPS cell-derived NKT cell therapy, the company exercised its option rights in November 2022 to acquire an exclusive development, manufacturing, and sales license from RIKEN, and is conducting the world's first clinical trial using iPS-NKT cells for head and neck cancer. Additionally, the company is advancing the development of CAR-T cell therapy for solid tumors. BrightPath Biotherapeutics is also developing antibody drugs targeting molecules that suppress cancer immunity, aiming to innovate cancer treatment through multiple approaches.